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A B S T R A C T
Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab
chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies.
A retrospective analysis was performed of women who received platinum/bevacizumab (PB) chemotherapy
for cervical cancer at Washington University between July 1, 2005 and December 31, 2015. Wilcoxon rank-sum
exact test and Fisher's exact test were used to compare the treatment groups, and Kaplan Meier curves were
generated. Cox regression analyses were performed, with treatment free interval and prior therapy response
included as covariates.
Of 84 patients who received PB chemotherapy, 59 (70%) received no second line chemotherapy, as they did
not recur, progressed without further chemotherapy, were lost to follow up, or expired. Of the remaining 25
patients, 9 were retreated with the combination of platinum/bevacizumab (PB), 6 were retreated with a pla-
tinum regimen without bevacizumab (P), and 10 were retreated with neither (not-P). The only long-term sur-
vivor was in the not-P group and was treated with an immunotherapy agent. Median overall survival of all
patients was 7.1 months. There was a marginal diﬀerence in survival between women in the PB and not-PB
groups (11.8 versus 5.7 months; HR 3.02, 95% CI, 0.98–9.28). There was no diﬀerence in survival based on
platinum interval (HR 0.81; 95% CI, 0.27–2.45).
Outcomes are grim for women retreated after platinum/bevacizumab therapy and are only marginally im-
proved by retreatment with a platinum/bevacizumab regimen. Rather than additional PB therapy, women with
cervical cancer who recur after platinum/bevacizumab should consider supportive care or clinical trials.
1. Introduction
Although largely preventable through screening and vaccination
(Sasieni et al., 1996; Harper & DeMars, 2017; Rijkaart et al., 2012),
cervical cancer remains a deadly disease, with especially poor outcomes
following diagnosis of advanced or recurrent cervical cancer (Peiretti
et al., 2012; Hequet et al., 2013; Moore, 2008). Cure of recurrent me-
tastatic cervical cancer is rare (Khoury-Collado et al., 2007). Combining
platinum agents with bevacizumab can lead to dramatic and prolonged
disease response among women with metastatic cervical cancer (Tewari
et al., 2014; Zighelboim et al., 2013). Previously, median survival after
treatment with cisplatin was only 6.5 months (Long et al., 2005),
augmented by adding a second agent, such as topotecan or paclitaxel, to
9–13 months (Monk et al., 2009). Adding bevacizumab to the combi-
nation of cisplatin and paclitaxel increased the median survival to up to
17 months, and a substantial proportion of women treated with a pla-
tinum/bevacizumab combination have had complete responses and
have survived for relatively long periods free of disease (Tewari et al.,
2014; Zighelboim et al., 2013). However, previously unexplored is
whether retreatment will have similar results.
Because the introduction of bevacizumab to combination che-
motherapy regimens has been so recent, there is insuﬃcient evidence to
guide counseling for cervical cancer patients who require retreatment
after prior platinum/bevacizumab therapy. Critical questions include
whether to attempt treatment again with a platinum drug and whether
to incorporate bevacizumab into the new regimen. It is also unclear
what prognosis women might expect after retreatment. This study aims
to assess overall survival after subsequent chemotherapy for women
who recur after prior treatment with platinum/bevacizumab che-
motherapy and to compare survival after re-treatment with platinum/
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bevacizumab chemotherapy to survival after other regimens.
2. Materials and methods
This study was approved by Washington University's Institutional
Review Board. We identiﬁed all patients treated concomitantly with a
platinum agent and bevacizumab for cervical cancer at Washington
University between July 1, 2005 and December 31, 2015 using a da-
tabase of gynecologic cancer patients. A retrospective chart review was
performed. We identiﬁed 84 patients who received a combination
therapy of a platinum and bevacizumab (PB) for cervical cancer. These
patients received platinum and bevacizumab therapy in combination
with either a taxane, topotecan or alternative regimen. The use of cis-
platin/taxol/bevacizumab, as described in GOG 240, was not a re-
quirement for inclusion.
We used descriptive statistics to summarize demographic and clin-
ical characteristics of patients, stratiﬁed by which treatment they re-
ceived for their second recurrence or progressive disease (PB for pla-
tinum-bevacizumab retreatment and not-PB for treatment with an
alternate regimen). The not-PB group was divided into those who re-
ceived a platinum agent as part of the treatment for the recurrence or
progressive disease (P) and those who did not (not-P). Progression
through the initial PB treatment for a ﬁrst recurrence was deﬁned by
the RECIST criteria or by the interpretation in the attending oncologist's
notes. Overall survival was calculated to be the time from the day of the
ﬁrst chemotherapy cycle for treatment of their recurrence or pro-
gressive disease (T = 0) to the date of death. Dates of death were found
either in our hospital's electronic medical record or through a search of
public obituaries.
Due to the small sample size and non-normality feature of the data,
Wilcoxon rank-sum exact test was conducted to compare the medians of
the continuous variables, and Fisher's exact test was performed to
compare the proportions of the categorical variables between the
treatment groups, PB and not-PB. Kaplan Meier curves were generated,
and a log-rank test was used for the comparison of survival distributions
between the treatment groups as well as the treatment free in-
terval < 6 months and ≥6 months.
Cox regression analyses were performed to estimate unadjusted
hazard ratios and adjusted hazard ratios. In addition to the variable of
interest (bevacizumab vs non-bevacizumab containing therapy) factors
associated with overall survival at a signiﬁcance level of P = 0.25 or
lower were entered into multivariable analysis. Treatment free interval
and prior therapy response were included in the regression models as
covariates. When excluding the one case of immunotherapy, there was
no censored case in our study cohort. Thus, Wilcoxon rank-sum exact
test was conducted to compare the survival time medians between
treatment groups as well as between the treatment free interval groups.
All statistical analyses were performed using SAS (Version 9.4, SAS
Institute Inc., Cary, NC). P-value < 0.05 was considered to be statis-
tically signiﬁcant.
3. Results
Eighty-four patients were identiﬁed who were treated with pla-
tinum-bevacizumab at our institution between July 1, 2005 and
December 31, 2015. Of these, 59 received PB as their ultimate therapy,
because they did not recur (n = 15), they progressed without further
chemotherapy (n = 6), they were lost to follow up (n = 9), or they
expired (n = 29). One of these patients was excluded because she de-
veloped myelodysplastic syndrome after the diagnosis of cervical
cancer recurrence and was therefore unable to receive chemotherapy
speciﬁc to cervical cancer. We identiﬁed 9 patients who received a
platinum agent and bevacizumab and who were subsequently retreated
with a platinum/bevacizumab combination (PB). Sixteen patients re-
ceived PB followed by a subsequent, not-PB, chemotherapy (not-PB),
including 6 retreated with a platinum (P) and 10 treated with a
Table 1
Patient demographics and initial treatment regimens.
Not-PB
PB
N = 9 (%)
Not-PB
N = 16 (%)
P
N = 6 (%)
Not-P




Age at initial PB, median (range) 52.0 (36.0–63.0) 48.5 (22.0, 67.0) 58.0 (33.0–67.0) 44.0 (22.0, 54.0) 64.0 0.57
FIGO_stage2 0.44
I 1 (11.1) 5 (31.3) 1 (16.7) 3 (33.3) 1
II 2 (22.2) 6 (37.5) 4 (66.7) 2 (22.2) 0
III 2 (22.2) 2 (12.5) 0 (0.0) 2 (22.2) 0
IV 4 (44.4) 3 (18.8) 1 (16.7) 2 (22.2) 0
Histology 0.25
Squamous cell carcinoma 5 (55.6) 12 (75.0) 4 (66.7) 7 (77.8) 1
Adenocarcinoma 2 (22.2) 4 (25.0) 2 (33.3) 2 (22.2) 0
Adenosquamous 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 0
Small cell 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 0
Race 1.00
White non-Hispanic 8 (88.9) 13 (81.3) 4 (66.7) 8 (88.9) 1
African American 1 (11.1) 2 (12.5) 1 (16.7) 1 (11.1) 0
Asian 0 (0.0) 1 (6.3) 1 (16.7) 0 (0.0) 0
Insurance status 0.35
Medicare/Private 8 (88.9) 10 (62.5) 3 (50.0) 6 (66.7) 1
Medicaid/Self-Pay 1 (11.1) 6 (37.5) 3 (50.0) 3 (33.3) 0
Smoking status 0.86
Current 2 (22.2) 5 (31.3) 2 (33.3) 3 (33.3) 0
Former 1 (11.1) 3 (18.8) 1 (16.7) 2 (22.2) 0
Never 6 (66.7) 8 (50.0) 3 (50.0) 4 (44.4) 1
Initial therapy 0.35
Cisplatin + radiation 5 (55.6) 12 (75.0) 5 (83.3) 6 (66.7) 1
Surgery + chemoradiation 2 (22.2) 0 (0.0) 0 (0.0) 0 (0.0) 0
Radiation 0 (0.0) 1 (6.3) 0 (0.0) 1 (11.1) 0
Chemotherapy 1 (11.1) 1 (6.3) 1 (16.7) 0 (0.0) 0
Other chemotherapy + radiation 1 (11.1) 2 (12.5) 0 (0.0) 2 (22.2) 0
⁎ For the comparison of women receiving platinum-bevacizumab combination therapy vs women receiving other regimens.
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non‑platinum regimen (not-P). There were no patients treated with
bevacizumab maintenance therapy.
As shown in Table 1, of twenty-ﬁve patients included in the ana-
lysis, we did not identify diﬀerences in age, race, stage, histology, in-
surance status and smoking status between the PB and not-PB groups.
Results of initial and subsequent therapy are shown in Table 2. Most
women had received cisplatin and radiation as initial therapy, prior to
recurrence and treatment with platinum/bevacizumab (5/9 in the PB
group and 12/16 in the not-PB group). All but two patients received
initial PB for recurrent cervical cancer. Of the two who received initial
PB as their ﬁrst treatment, one was in the PB group and one in the P
group. We found no diﬀerences in the number of cycles of initial PB
treatment; the median number of cycles for women in the PB and not-
PB groups was each 6. We also found no diﬀerences between the two
groups in their responses to the initial PB treatment.
As shown in Table 2, responses to subsequent treatment were low:
0% of PB patients and only 6% of not-PB patients had a partial re-
sponse to retreatment (p = 1.00). 88.9% of PB patients and 93.8% of
not-PB patients had stable or progressive disease following subsequent
chemotherapy. One PB patient elected to pursue alternative treat-
ments after completion of PB re-treatment prior to imaging doc-
umenting disease status. In all patients, the primary reason for dis-
continuation of subsequent treatment regardless of therapy was
disease progression.
Of all patients included in the study, median survival was
7.1 months (range 1.5–28.8 months). All died except one treated with
immunotherapy with attenuated Listeria encoding HPV16 E7, who was
excluded from further analyses. As shown in Fig. 1, compared to women
in the PB group, women in the not-PB group lived 6.1 fewer months
(11.8 months in the PB group; 5.74 months in the not-PB group, HR
3.20; 95% CI, 1.19–8.60). Because of their marginal association with
survival (P = 0.25), we adjusted for treatment free interval and prior
therapy response; after adjustment, the diﬀerence in survival between
the two groups was marginal (HR 3.02; 95% CI, 0.98–9.28). Although
few patients survived> 15 months, one patient did live for almost
2.5 years after initiating retreatment with PB.
We sought evidence for “platinum sensitivity” among women re-
treated with platinum after initial PB therapy. We compared those who
received platinum as a component of their subsequent treatment, in-
cluding the PB (n = 9) and P groups (n = 6). Survival curves of these
two groups are shown in Fig. 2. Patients with more than a 6-month
interval between the last cycle of their initial PB regimen and the ﬁrst
cycle of their subsequent treatment (either PB or P) lived only
3.4 months longer than those with treatment-free intervals of less than
or equal to 6 months (HR 0.81; 95% CI, 0.27–2.45).
4. Discussion
Our study suggests that subsequent treatment with platinum/bev-
acizumab after previous treatment with the same yields a negligible
response rate with a marginal impact on survival. Re-treatment of
metastatic cervical cancer with PB combinations after prior PB combi-
nation therapy only occasionally resulted in long-term remission, with a
median survival of 11.8 months. While just above the threshold for
statistical signiﬁcance and limited by the small sample size, these
ﬁndings are suggestive, and should prompt others to explore this
question. Any decision to re-treat with PB must be carefully discussed
and considered by the oncologist and patient. One notable ﬁnding of
this study was that the only patient to survive received not PB re-
treatment but an experimental immunotherapy agent. As Ring et al.
have demonstrated, diﬀerences between the density of cytotoxic T cells
in intra- and peritumoral stroma make immunotherapy targets a
Table 2













Number of cycles - initial PB, median (range) 6.0 (3.0, 9.0) 6.0 (2.0, 12.0) 7.0 (3.0, 12.0) 6.0 (2.0, 11.0) 6.0 0.83
Response to initial PB 0.20
Complete Response 4 (44.4) 3 (18.8) 2 (33.3) 0 1
Stable/progression 5 (55.6) 13 (81.3) 4 (66.7) 9 (100.0) 0
Treatment free interval in months, median (range) 6.3 (0.7, 15.4) 1.6 (0.6, 19.8) 5.1 (1.2, 19.8) 1.2 (0.6, 3.2) 10.7 0.25
≤6mon 4 (44.4) 12 (75.0) 3 (50.0) 9 (100.0) 0 0.20
> 6mon 5 (55.6) 4 (25.0) 3 (50.0) 0 1
Number of cycles - subsequent treatment, median (range) 6.0 (3.0, 9.0) 3.0 (1.0, 8.0) 3.5 (1.0, 8.0) 3.0 (1.0, 4.0) 3.0 0.008
Response to subsequent treatment 1.00
Partial Response 0 1 (6.3) 1 (16.7) 0 0
Stable/progression 8 (88.9) 15 (93.8) 5 (83.3) 9 (100.0) 1
Unknown (Lost to follow up after treatment completion) 1 (11.1) 0 0 0 0
Reason for discontinuation of subsequent treatment 1.00
Progressive disease 7 (77.8) 13 (81.3) 5 (83.3) 8 (88.9) 0
Toxicity 1 (11.1) 1 (6.3) 0 0 1
Pursuit of alternative treatments 1 (11.1) 2 (12.5) 1 (16.7) 1 (11.1) 0
⁎ For the comparison of women receiving platinum-bevacizumab combination therapy vs women receiving other regimens.
Fig. 1. Overall survival estimates: Comparing re-treatment with platinum/bevacizumab
and treatment with an alternative regimen.
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potential future for treatment of recurrent cervical cancer (Ring et al.,
2017). Similarly, Howitt et al. have suggested that therapies targeting
PD−1 may prove beneﬁcial in these patients, who have few other
options (Howitt et al., 2016). Given these ﬁndings, as well as ours,
women with cervical cancer who have persistent or progressive disease
after a ﬁrst course of PB should be counseled to consider clinical trials,
including immunotherapy, or supportive care, given that further con-
ventional chemotherapy does not only not lead to cure, but is also
unlikely to result in substantial additional survival time.
We did not ﬁnd evidence to support a concept of “platinum sensi-
tivity” after prior platinum therapy for cervical cancer. We analyzed
patients who were re-treated with platinum therapy and compared their
survival based on their treatment free intervals (TFI). While those with
a TFI of> 6 months survived three months longer, this was neither
statistically nor clinically signiﬁcant. However, this should be validated
by studies that include patients who receive therapies other than pla-
tinum/bevacizumab, as had been a speciﬁc inclusion criteria for this
investigation. Others have previously investigated the concept of pla-
tinum sensitivity in cervical cancer, but with diﬀering opinions.
Takekuma et al. found that a PFI of 12 months had a strong relationship
to the response to subsequent chemotherapy, but the study focused on
re-administration of cisplatin versus a cisplatin analog (Takekuma
et al., 2015). Matoda et al. found that a PFI of 24 months was the
discriminating point in response diﬀerence (Matoda et al., 2013),
however, we had no patients with greater than a 24 month TFI so were
unable to replicate the analysis.
Limitations of this study include that it was a retrospective study at
a single institution, therefore limited by the speciﬁc trends of che-
motherapy use among a small group of physicians. It was also limited in
the fact that we were naturally unable to include women who have
been treated with PB for a ﬁrst recurrence but have subsequently not
recurred. At our institution, many of these women completed initial
treatment with PB in the last 3 years, and as such, we do not yet have
the data on their response to a subsequent recurrence's treatment. Since
the use of the PB combination therapy is relatively new, future studies
are necessary to evaluate how this chemotherapy trend aﬀects out-
comes. Larger series are needed to assess whether women who showed
complete response to an initial PB treatment have increased survival
when they are retreated with the same.
This study was also limited in that there was no control for down-
stream chemotherapies following subsequent PB treatment. Four out of
the 9 patients in the PB group were treated with a chemotherapy re-
gimen following subsequent PB. One of these patients was treated with
two subsequent regimens; she progressed on each. Similarly, four pa-
tients in the not-P group received subsequent chemotherapy treatments.
One received three future therapies and progressed on each.
In conclusion, women with cervical cancer after PB therapy face
diﬃcult choices, and supportive care may be a rational option for
many. Retreatment with PB is associated with marginally better sur-
vival but few patients survive beyond a year. Clinical trials may oﬀer
the best hope.
References
Harper, D.M., LR, DeMars, 2017. HPV vaccines – a review of the ﬁrst decade. Gynecol.
Oncol.
Hequet, D., Marchand, E., Place, V., Fourchotte, V., De La Rochefordière, A., Dridi, S.,
et al., 2013. Evaluation and impact of residual disease in locally advanced cervical
cancer after concurrent chemoradiation therapy: Results of a multicenter study. Eur.
J. Surg. Oncol. 39 (12), 1428–1434.
Howitt, B.E., Sun, H.H., Roemer, M.G., Kelley, A., Chapuy, B., Aviki, E., et al., 2016.
Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and
vulva. JAMA Oncol. 2 (4), 518–522.
Khoury-Collado, F., Bowes, R.J., Jhamb, N., Aghajanian, C., Abu-Rustum, N.R., 2007.
Unexpected long-term survival without evidence of disease after salvage che-
motherapy for recurrent metastatic cervical cancer: a case series. Gynecol. Oncol. 105
(3), 823–825.
Long HJ, 3rd, Bundy BN, Grendys EC, Jr., Benda JA, McMeekin DS, Sorosky J, et al.
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the
uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol.
2005;23(21):4626–33.
Matoda, M., Tanigawa, T., Omatsu, K., Ushioda, N., Yamamoto, A., Okamoto, S., et al.,
2013. Platinum-free interval in second-line chemotherapy for recurrent cervical
cancer. Int. J. Gynecol. Cancer 23 (9), 1670–1674.
Monk, B.J., Sill, M.W., McMeekin, D.S., Cohn, D.E., Ramondetta, L.M., Boardman, C.H.,
et al., 2009. Phase III trial of four cisplatin-containing doublet combinations in stage
IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group
study. J. Clin. Oncol. 27 (28), 4649–4655.
Moore, D.H., 2008. Chemotherapy for advanced, recurrent, and metastatic cervical
cancer. J. Natl. Compr. Cancer Netw. 6 (1), 53–57.
Peiretti, M., Zapardiel, I., Zanagnolo, V., Landoni, F., Morrow, C.P., Maggioni, A., 2012.
Management of recurrent cervical cancer: a review of the literature. Surg. Oncol. 21
(2), e59–66.
Rijkaart, D.C., Berkhof, J., Rozendaal, L., van Kemenade, F.J., Bulkmans, N.W.,
Heideman, D.A., et al., 2012. Human papillomavirus testing for the detection of high-
grade cervical intraepithelial neoplasia and cancer: ﬁnal results of the POBASCAM
randomised controlled trial. Lancet Oncol. 13 (1), 78–88.
Ring, K.L., Yemelyanova, A.V., Soliman, P.T., Frumovitz, M.M., Jazaeri, A.A., 2017.
Potential immunotherapy targets in recurrent cervical cancer. Gynecol. Oncol.
Sasieni, P.D., Cuzick, J., Lynch-Farmery, E., 1996. Estimating the eﬃcacy of screening by
auditing smear histories of women with and without cervical cancer. The National
Coordinating Network for Cervical Screening Working Group. Br. J. Cancer 73 (8),
1001–1005.
Takekuma, M., Kuji, S., Tanaka, A., Takahashi, N., Abe, M., Hirashima, Y., 2015. Platinum
sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent
cervical cancer. J. Gynecol. Oncol. 26 (3), 185–192.
Tewari KS, Sill MW, Long HJ, 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved
survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med.
2014;370(8):734–43.
Zighelboim, I., Wright, J.D., Gao, F., Case, A.S., Massad, L.S., Mutch, D.G., et al., 2013.
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or
persistent cervical cancer. Gynecol. Oncol. 130 (1), 64–68.
Fig. 2. Exploring the platinum-free interval: Overall survival comparison between pa-
tients re-treated with a platinum chemotherapy within six months versus after six months.
A.S. Zamorano et al. Gynecologic Oncology Reports 22 (2017) 48–51
51
